[go: up one dir, main page]

BR0014138A - Uso de um vetor adenoviral deficiente em replicação, e, métodos para reforçar, e para induzir resposta imune de célula cd8+ t a um antìgeno em um indivìduo - Google Patents

Uso de um vetor adenoviral deficiente em replicação, e, métodos para reforçar, e para induzir resposta imune de célula cd8+ t a um antìgeno em um indivìduo

Info

Publication number
BR0014138A
BR0014138A BR0014138-0A BR0014138A BR0014138A BR 0014138 A BR0014138 A BR 0014138A BR 0014138 A BR0014138 A BR 0014138A BR 0014138 A BR0014138 A BR 0014138A
Authority
BR
Brazil
Prior art keywords
antigen
replication
individual
immune response
adenoviral vector
Prior art date
Application number
BR0014138-0A
Other languages
English (en)
Inventor
Joerg Schneider
Sarah Catherine Gilbert
Carolyn Mary Hannan
Adrian Vivian Sinton Hill
Original Assignee
Isis Innovation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=10861351&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BR0014138(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Isis Innovation filed Critical Isis Innovation
Publication of BR0014138A publication Critical patent/BR0014138A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/002—Protozoa antigens
    • A61K39/015—Hemosporidia antigens, e.g. Plasmodium antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5256—Virus expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5258—Virus-like particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

"USO DE UM VETOR ADENOVIRAL DEFICIENTE EM REPLICAçãO, E, MéTODOS PARA REFORçAR, E PARA INDUZIR RESPOSTA IMUNE DE CéLULA CD8+ T A UM ANTìGENO EM UM INDIVìDUO". Uso de um vetor adenoviral deficiente em replicação codificando um antígeno ou epítopo de célula CD8+ T do antígeno para reforçar, no indivíduo, uma resposta imune de célula CD8+ T ao antígeno após administração anterior de uma composição de iniciação. A composição de iniciação compreende o antígeno ou epítopo ou ácido nucleico codificando o antígeno ou epítopo e pode ser DNA, Ty-LVP's ou vírus ankara modificado (MVA). A administração pode ser intradérmica ou intramuscular.
BR0014138-0A 1999-09-21 2000-09-20 Uso de um vetor adenoviral deficiente em replicação, e, métodos para reforçar, e para induzir resposta imune de célula cd8+ t a um antìgeno em um indivìduo BR0014138A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9922361.2A GB9922361D0 (en) 1999-09-21 1999-09-21 Generating an immune response to an antigen
PCT/GB2000/003601 WO2001021201A2 (en) 1999-09-21 2000-09-20 Use of replication-deficient adenoviral vector to boost cd8+ t cell immune response to antigen

Publications (1)

Publication Number Publication Date
BR0014138A true BR0014138A (pt) 2002-05-21

Family

ID=10861351

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0014138-0A BR0014138A (pt) 1999-09-21 2000-09-20 Uso de um vetor adenoviral deficiente em replicação, e, métodos para reforçar, e para induzir resposta imune de célula cd8+ t a um antìgeno em um indivìduo

Country Status (12)

Country Link
EP (2) EP1612269A1 (pt)
JP (1) JP2003509470A (pt)
CN (1) CN1391609A (pt)
AT (1) ATE295421T1 (pt)
AU (1) AU762894B2 (pt)
BR (1) BR0014138A (pt)
CA (1) CA2384806A1 (pt)
DE (1) DE60020136T2 (pt)
DK (1) DK1214416T3 (pt)
ES (1) ES2241653T3 (pt)
GB (1) GB9922361D0 (pt)
WO (1) WO2001021201A2 (pt)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9711957D0 (en) 1997-06-09 1997-08-06 Isis Innovation Methods and reagents for vaccination
WO2001002607A1 (en) 1999-07-06 2001-01-11 Merck & Co., Inc. Adenovirus carrying gag gene hiv vaccine
US6733993B2 (en) 2000-09-15 2004-05-11 Merck & Co., Inc. Enhanced first generation adenovirus vaccines expressing codon optimized HIV1-gag, pol, nef and modifications
GB0118532D0 (en) * 2001-07-30 2001-09-19 Isis Innovation Materials and methods relating to improved vaccination strategies
US20050123561A1 (en) * 2002-05-20 2005-06-09 Mitsuo Honda Radio lan access authentication system
US20080153083A1 (en) 2003-10-23 2008-06-26 Crucell Holland B.V. Settings for recombinant adenoviral-based vaccines
AU2003288273A1 (en) 2002-10-23 2004-05-13 Crucell Holland B.V. New settings for recombinant adenoviral-based vaccines
CN100410382C (zh) * 2006-08-18 2008-08-13 上海交通大学医学院 一种可诱生细胞免疫应答的共表达载体和真核表达载体
CN101522211A (zh) * 2006-11-17 2009-09-02 基因特伦尼克斯公司 使用电穿孔辅助疫苗接种和加强免疫来增强免疫反应的方法
GB0706914D0 (en) * 2007-04-10 2007-05-16 Isis Innovation Novel adenovirus vectors
GB0706912D0 (en) * 2007-04-10 2007-05-16 Isis Innovation Novel viral vaccines
US9096868B2 (en) * 2007-09-14 2015-08-04 Institut Pasteur Polynucleotides allowing the expression and secretion of recombinant pseudo-virus containing foreign epitopes, their production, and use
GB0823497D0 (en) * 2008-12-24 2009-01-28 Isis Innovation Immunogenic composition and use thereof
US9828414B2 (en) * 2012-10-28 2017-11-28 Bavarian Nordic A/S Pr13.5 promoter for robust T-cell and antibody responses
AU2018235130B2 (en) 2017-03-15 2023-12-07 Oxford Biomedica (Uk) Limited Method
CA3157667A1 (en) * 2019-10-16 2021-04-22 Cancer Research Technology Limited Vector for cancer treatment
WO2023105221A1 (en) 2021-12-07 2023-06-15 Vaccitech (Uk) Limited Vaccine boost methods and compositions
WO2024218165A1 (en) 2023-04-17 2024-10-24 Barinthus Biotherapeutics (Uk) Limited Hpv viral vector vaccine

Also Published As

Publication number Publication date
ES2241653T3 (es) 2005-11-01
ATE295421T1 (de) 2005-05-15
JP2003509470A (ja) 2003-03-11
EP1214416B1 (en) 2005-05-11
WO2001021201A2 (en) 2001-03-29
DE60020136D1 (de) 2005-06-16
GB9922361D0 (en) 1999-11-24
AU7302400A (en) 2001-04-24
EP1612269A1 (en) 2006-01-04
DK1214416T3 (da) 2005-08-29
WO2001021201A3 (en) 2001-10-18
EP1214416A2 (en) 2002-06-19
CN1391609A (zh) 2003-01-15
DE60020136T2 (de) 2006-02-23
CA2384806A1 (en) 2001-03-29
AU762894B2 (en) 2003-07-10

Similar Documents

Publication Publication Date Title
BR0014138A (pt) Uso de um vetor adenoviral deficiente em replicação, e, métodos para reforçar, e para induzir resposta imune de célula cd8+ t a um antìgeno em um indivìduo
DE69734882D1 (de) Dna immunisierung gegen chlamydia infektion
NO20013701L (no) HER-2/neu-fusjonsproteiner
WO2002061113A3 (en) Nucleic acid derived vaccine that encodes an antigen linked to a polypeptide that promotes antigen presentation
ATE332965T1 (de) Komplementierende zellinien
WO2008011609A3 (en) Compositions and methods for vaccinating against hsv-2
DK0957935T3 (da) Chlamydia-vacciner og immunogene præparater indeholdende et ydre membran-antigen samt fremgangsmåde til fremstilling deraf
BR9913446A (pt) Produtos de aglicona e métodos de uso
BR9811475A (pt) Conjugados imunogênicos compreendendo uma porina meningocóccica de grupo b e um polissacarìdeo de h. influenzae
BR0308755A (pt) Misturas de tintura de azo reativas à fibra, preparação e uso das mesmas
CY1105604T1 (el) Μεθοδος ενισχυσης ανοσων απαντησεων στο εμβολιο κατα του ιου του απλου ερπητα
JP2003509470A5 (pt)
NO984244L (no) Vaksinesammensetninger og fremgangsmÕter som er nyttige i Õ indusere immunbeskyttelse mot artritogene peptider som er involvert i patogenese av reumatoid artritt
DE69230671D1 (de) Impfstoffe gegen actinobacillus pleuropneumonie
WO2003011331A3 (en) Materials and methods relating to improved vaccination strategies
Capozzo et al. Development of DNA vaccines against hemolytic-uremic syndrome in a murine model
DK0752888T3 (da) Nukleotid- og aminosyresekvenser af gB, gC- og gD-hunde-herpesvirus og anvendelser deraf
AU8467201A (en) Compositions for and methods of using herpes simplex virus glycoprotein d to suppress immune responses
Föhring et al. Adenovirus type 12 specific cell surface antigen in transformed cells is a product of the E1b early region
BRPI0209416A2 (pt) Novos vetores de expressão e uso dos mesmos
DE69937258D1 (de) Genetische impstoffe mit adjuvans
BR0013574A (pt) Antìgeno vacina de moraxella
DK0524421T3 (da) Humant herpesvirus type 6 protein p 100, de tilsvarende DNA-sekvenser, deres fremstilling og anvendelse
WO2000024430A3 (es) Caracterizacion y conservacion de formulaciones vacunales
BR0213554A (pt) Timosina para aumento da imunização genética

Legal Events

Date Code Title Description
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: INDEFIRO O PEDIDO DE ACORDO COM O(S) ARTIGO(S) 8O, 10 (VIII), 11, 13, 24 E 25 DA LPI.

B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: MANTIDO O INDEFERIMENTO UMA VEZ QUE NAO FOI APRESENTADO RECURSO DENTRO DO PRAZO LEGAL.